CO5640125A2 - Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la piel - Google Patents
Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la pielInfo
- Publication number
- CO5640125A2 CO5640125A2 CO03105192A CO03105192A CO5640125A2 CO 5640125 A2 CO5640125 A2 CO 5640125A2 CO 03105192 A CO03105192 A CO 03105192A CO 03105192 A CO03105192 A CO 03105192A CO 5640125 A2 CO5640125 A2 CO 5640125A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapeutic agent
- composition
- prodrug
- methyl
- hydrogen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 6
- 229940124597 therapeutic agent Drugs 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000005462 imide group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000012088 reference solution Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000245 skin permeability Toxicity 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Una composición farmacéutica tópica que comprende un agente tempéutico en una cantidad terapéuticamente efectivo solubilizado en una cantidad solubilizante de un vehículo farmacéuticamente aceptable que comprende un alcohol monohídrico de bajo peso molecular, en donde (a) el agente terapéutico comprende por lo menos un fármaco inhibidor selectivo de la COX- 2 o un pro- fármaco del mismo, y (b) una muestra de prueba de la composición proporciona una tasa de permeabilidad de piel del agente terapéutico por lo menos igual al proporcionado por una solución de referencia del agente terapéutico en etanol acuoso al 70%.2.- La composición de la Reivindicación 1 en donde esencialmente todo el agente terapéutico presente es forma solubilizada.3.- La composición de la Reivindicación 1 en donde el agente terapéutico comprende por lo menos un compuesto de fórmula donde R3 es un grupo metilo, amino, o imida, R4 es hidrógeno o un grupo alquilo C1-4 o alcoxilo, X es N o CR5 en donde R5 es hidrógeno o halógeno, e Y, y Z son cada uno independientemente átomos de carbono o nitrógeno definiendo átomos adyacentes de un anillo de cinco a seis miembros el cual es no sustituido o sustituido sobre una o más posiciones por grupos oxo, halo, metilo o halometilo; o un isómero, tautómero, sal farmacéuticamente aceptable o pro- fármaco del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29483801P | 2001-05-31 | 2001-05-31 | |
US35075601P | 2001-11-13 | 2001-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5640125A2 true CO5640125A2 (es) | 2006-05-31 |
Family
ID=26968778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO03105192A CO5640125A2 (es) | 2001-05-31 | 2003-11-28 | Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la piel |
Country Status (25)
Country | Link |
---|---|
US (1) | US20030161867A1 (es) |
EP (1) | EP1404345A2 (es) |
JP (1) | JP2004532871A (es) |
KR (1) | KR20040033286A (es) |
CN (1) | CN1547474A (es) |
AP (1) | AP2003002922A0 (es) |
BR (1) | BR0210104A (es) |
CA (1) | CA2448627A1 (es) |
CO (1) | CO5640125A2 (es) |
CR (1) | CR7173A (es) |
CZ (1) | CZ20033241A3 (es) |
EA (1) | EA200301200A1 (es) |
EC (1) | ECSP034869A (es) |
HU (1) | HUP0600294A2 (es) |
IL (1) | IL159100A0 (es) |
IS (1) | IS7055A (es) |
MA (1) | MA27030A1 (es) |
MX (1) | MXPA03010991A (es) |
NO (1) | NO20035325D0 (es) |
OA (1) | OA12613A (es) |
PL (1) | PL367337A1 (es) |
SK (1) | SK14762003A3 (es) |
TN (1) | TNSN03127A1 (es) |
WO (1) | WO2002096435A2 (es) |
ZA (1) | ZA200309298B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4283507B2 (ja) * | 2002-08-02 | 2009-06-24 | 久光製薬株式会社 | 経皮投与用貼付剤 |
US20050020658A1 (en) * | 2002-11-21 | 2005-01-27 | Katsuyuki Inoo | Selective cyclooxygenase-2 inhibitor patch |
US20040127531A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor |
US20040126415A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor |
ES2344062T5 (es) * | 2003-01-23 | 2013-04-26 | Shire Biopharmaceuticals Holdings Ireland Limited | Formulación y procedimientos para el tratamiento de la trombocitopenia |
EP1673079A1 (en) * | 2003-10-08 | 2006-06-28 | Novartis AG | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
WO2005044227A1 (en) * | 2003-11-05 | 2005-05-19 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions |
US7666914B2 (en) * | 2004-06-03 | 2010-02-23 | Richlin David M | Topical preparation and method for transdermal delivery and localization of therapeutic agents |
KR20070097092A (ko) * | 2005-01-14 | 2007-10-02 | 리포 케미컬즈 인크. | 과다색소침착된 피부 치료용 조성물 및 치료방법 |
AR054336A1 (es) * | 2005-03-30 | 2007-06-20 | Astion Dev As | Tratamiento de enfermedades dermatologicas y del prurito |
RS50693B (sr) * | 2005-06-14 | 2010-06-30 | Uni-Pharma Kleon Tsetis Pharmaceutical | Stabilni farmaceutski gel diklofenak natrijuma |
US20070243275A1 (en) * | 2006-04-13 | 2007-10-18 | Gilbard Jeffrey P | Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
US20120040809A1 (en) | 2010-08-11 | 2012-02-16 | Formicola Thomas M | Stretch-Out Roll Up Bar |
FR2905601A1 (fr) * | 2006-09-11 | 2008-03-14 | Innoderm Sarl | Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques. |
JP5432716B2 (ja) | 2006-10-17 | 2014-03-05 | ヌーボ リサーチ インコーポレイテッド | ジクロフェナクゲル |
US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
US7910597B2 (en) | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
HU227970B1 (en) * | 2007-07-10 | 2012-07-30 | Egis Gyogyszergyar Nyrt | Pharmaceutical compositions containing silicones of high volatility |
DE102007034976A1 (de) | 2007-07-26 | 2009-01-29 | Bayer Healthcare Ag | Arzneimittel zur transdermalen Anwendung bei Tieren |
CA2730787A1 (en) | 2008-07-16 | 2010-01-21 | David M. Cohen | Topical drug delivery system |
ES2414158T3 (es) | 2008-10-20 | 2013-07-18 | Unilever Nv | Una composición antimicrobiana |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
NZ596254A (en) | 2009-05-01 | 2013-06-28 | Advanced Vision Res Inc | Cleanser compositions and methods for using the same comprising linalool, hinokitiol, diol and surfactant |
PL2480090T3 (pl) | 2009-09-24 | 2014-04-30 | Unilever Nv | Środek dezynfekujący zawierający eugenol, terpineol oraz tymol |
WO2011041609A2 (en) * | 2009-09-30 | 2011-04-07 | Nuvo Research Inc. | Topical formulations |
EP2485730A1 (en) | 2009-10-09 | 2012-08-15 | Nuvo Research Inc. | Topical formulation comprising etoricoxib and a zwitterionic surfactant |
EP2575813A1 (en) * | 2010-05-28 | 2013-04-10 | Nuvo Research Inc. | Topical etoricoxib formulation |
EA201201632A1 (ru) * | 2010-05-31 | 2013-04-30 | Юнилевер Н.В. | Композиция для ухода за кожей |
JP2012020991A (ja) * | 2010-06-16 | 2012-02-02 | Takasago Internatl Corp | 経皮吸収促進剤、及びこれを含有する皮膚外用製剤 |
CN103354741B (zh) | 2010-12-07 | 2016-01-13 | 荷兰联合利华有限公司 | 口腔护理组合物 |
CA2822683C (en) | 2011-01-04 | 2015-05-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
US20140057976A1 (en) * | 2011-03-31 | 2014-02-27 | Evocutis Plc | Usnic acid topical formulation |
KR20140077902A (ko) * | 2011-10-05 | 2014-06-24 | 더글라스 파머수티클스 엘티디. | 약학적 방법 및 아씨트레틴을 함유하는 국소 조성물 |
EP2773315B1 (en) | 2011-11-03 | 2015-07-08 | Unilever N.V. | A personal cleaning composition |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
US10045965B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
WO2014157727A1 (ja) * | 2013-03-29 | 2014-10-02 | 株式会社AskAt | 眼疾患治療剤 |
CA2932156A1 (en) * | 2013-12-24 | 2015-07-02 | The Procter & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
CA2966843A1 (en) * | 2014-11-10 | 2016-05-19 | Achelios Therapeutics, Inc. | Sprayable analgesic compositions |
LT3316857T (lt) | 2015-06-30 | 2021-11-25 | Sequessome Technology Holdings Limited | Daugiafazės kompozicijos |
CN105663032A (zh) * | 2016-02-23 | 2016-06-15 | 青岛科技大学 | 一种维他昔布软膏剂的制备方法 |
CN106267218A (zh) * | 2016-10-18 | 2017-01-04 | 华北理工大学 | 4‑萜品醇脂肪酸酯衍生物及其应用和制备方法 |
KR102042456B1 (ko) * | 2018-03-22 | 2019-11-08 | 크리스탈지노믹스(주) | 경피흡수제제 |
KR20210028609A (ko) * | 2018-05-31 | 2021-03-12 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 경피 흡수성 제제 |
RU2685436C1 (ru) * | 2018-06-22 | 2019-04-18 | ЗАО "ФармФирма "Сотекс" | Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей |
KR20220001170A (ko) | 2020-06-29 | 2022-01-05 | 김종림 | 앙카볼트 |
KR102619716B1 (ko) * | 2020-10-20 | 2023-12-29 | 고려대학교 산학협력단 | 저온에서도 우수한 항균활성을 갖는 항진균용 조성물 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
EP0828717B1 (en) * | 1995-05-25 | 2002-09-04 | G.D. SEARLE & CO. | Method of preparing 3-haloalkyl-1h-pyrazoles |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
GB2340751B (en) * | 1998-08-12 | 2003-11-05 | Edko Trading Representation | Pharmaceutical compositions |
ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
ATE288256T1 (de) * | 1999-01-14 | 2005-02-15 | Noven Pharma | Dermale zusammensetzungen |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
WO2000072883A2 (en) * | 1999-06-02 | 2000-12-07 | Aviana Biopharm | Pharmaceutical transdermal compositions |
IN191512B (es) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
WO2002005799A2 (en) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
IN191090B (es) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
-
2002
- 2002-05-30 CA CA002448627A patent/CA2448627A1/en not_active Abandoned
- 2002-05-30 WO PCT/US2002/017067 patent/WO2002096435A2/en not_active Application Discontinuation
- 2002-05-30 CZ CZ20033241A patent/CZ20033241A3/cs unknown
- 2002-05-30 PL PL02367337A patent/PL367337A1/xx not_active Application Discontinuation
- 2002-05-30 BR BR0210104-1A patent/BR0210104A/pt not_active IP Right Cessation
- 2002-05-30 HU HU0600294A patent/HUP0600294A2/hu unknown
- 2002-05-30 IL IL15910002A patent/IL159100A0/xx unknown
- 2002-05-30 CN CNA028149467A patent/CN1547474A/zh active Pending
- 2002-05-30 EP EP02774123A patent/EP1404345A2/en not_active Withdrawn
- 2002-05-30 JP JP2002592944A patent/JP2004532871A/ja not_active Withdrawn
- 2002-05-30 AP APAP/P/2003/002922A patent/AP2003002922A0/en unknown
- 2002-05-30 KR KR10-2003-7015581A patent/KR20040033286A/ko not_active Application Discontinuation
- 2002-05-30 SK SK1476-2003A patent/SK14762003A3/sk unknown
- 2002-05-30 US US10/158,342 patent/US20030161867A1/en not_active Abandoned
- 2002-05-30 OA OA1200300310A patent/OA12613A/en unknown
- 2002-05-30 TN TNPCT/US2002/017067A patent/TNSN03127A1/fr unknown
- 2002-05-30 MX MXPA03010991A patent/MXPA03010991A/es unknown
- 2002-05-30 EA EA200301200A patent/EA200301200A1/ru unknown
-
2003
- 2003-11-27 IS IS7055A patent/IS7055A/is unknown
- 2003-11-28 ZA ZA200309298A patent/ZA200309298B/xx unknown
- 2003-11-28 CO CO03105192A patent/CO5640125A2/es not_active Application Discontinuation
- 2003-11-28 CR CR7173A patent/CR7173A/es not_active Application Discontinuation
- 2003-11-28 NO NO20035325A patent/NO20035325D0/no not_active Application Discontinuation
- 2003-11-28 MA MA27417A patent/MA27030A1/fr unknown
- 2003-11-28 EC EC2003004869A patent/ECSP034869A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IS7055A (is) | 2003-11-27 |
MA27030A1 (fr) | 2004-12-20 |
EP1404345A2 (en) | 2004-04-07 |
NO20035325D0 (no) | 2003-11-28 |
CZ20033241A3 (cs) | 2004-08-18 |
CA2448627A1 (en) | 2002-12-05 |
PL367337A1 (en) | 2005-02-21 |
ECSP034869A (es) | 2004-07-23 |
BR0210104A (pt) | 2004-06-08 |
HUP0600294A2 (en) | 2007-02-28 |
IL159100A0 (en) | 2004-05-12 |
WO2002096435A2 (en) | 2002-12-05 |
TNSN03127A1 (fr) | 2005-12-23 |
CN1547474A (zh) | 2004-11-17 |
ZA200309298B (en) | 2004-05-12 |
SK14762003A3 (sk) | 2004-08-03 |
WO2002096435A3 (en) | 2003-05-01 |
CR7173A (es) | 2004-04-22 |
KR20040033286A (ko) | 2004-04-21 |
EA200301200A1 (ru) | 2004-06-24 |
MXPA03010991A (es) | 2004-02-27 |
JP2004532871A (ja) | 2004-10-28 |
US20030161867A1 (en) | 2003-08-28 |
OA12613A (en) | 2006-06-09 |
AP2003002922A0 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5640125A2 (es) | Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la piel | |
CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
PA8495101A1 (es) | Derivados de 13-metileritromicina | |
KR950031074A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
MXPA03005464A (es) | Agentes antivirales. | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
NO961136L (no) | Farmasöytisk formuleringsgrunnlag for nano-suspensjoner | |
DE60010076D1 (de) | Chinolinderivate als antibakterielle mittel | |
YU21803A (sh) | Farmaceutski aktivni derivati sulfonamida koji imaju i lipofilne i jonizujuće osobine kao inhibitori protein-junkinaza | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
EA200870545A1 (ru) | Новые гетероциклические соединения | |
DE60212949D1 (de) | Antivirale pyrazolopyridin verbindungen | |
ATE300541T1 (de) | Pyrazolopyridinderivate | |
ATE424200T1 (de) | Solubilisierte topoisomerase-gift-mittel | |
DE69931378D1 (de) | Chinazolin derivate und therapeutische verwendungen davon | |
NO20031410L (no) | Anvendelse av distamycinderivater for fremstilling av medikamenter | |
DK1412332T3 (da) | Quinolinderivater og anvendelse deraf som antitumormidler | |
ATE274515T1 (de) | Pyrazolopyridinderivate | |
HUP0303249A2 (hu) | Gombaellenes hatású vízoldékony triazolvegyületek és ezeket tartalmazó gyógyszerkészítmények | |
DE60222465D1 (de) | Pyrazolopyridin-derivate als antiherpesmittel | |
ATE246174T1 (de) | Tosylprolin-derivate als thymidylat-synthase inhibitoren | |
SE0301371D0 (sv) | New Compounds | |
EE05300B1 (et) | Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat | |
EE200200688A (et) | Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |